However, the subgroup analysis of TIP30 high expression and promoter methylation indicated that methylation of the TIP30 promoter was not significantly associated with a prolonged DFS for tumor patients (random model HR = 0.62, 95% CI: 0.19–2.02) (Figs 4 and 5). This evidence concerns the gene HTATIP2 and neoplasm.